Sat, Aug 23, 2014, 2:43 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

  • redstenox redstenox Dec 1, 2012 5:04 PM Flag

    ►► SNSS (exceptional review) ◄◄

    Trading volume Friday November 30, 2012 increase sparks review of Sunesis Pharmaceuticals, Inc.

    Trading on October 5, 2012 reveals a HOD of $6.85 that has technically retraced forming a solid base (floor) at just under $5 a share. Money flow indicators since retracing, point towards an influx into rather than out of SNSS stock.

    The catalyst: Vosaroxin in late stage trials for treating an aggressive cancer of the blood. Vosaroxin is Sunesis's most advanced currently experimental drug.

    A favorable outlook was taken when upsizing of the current trial took place as it was based on efficacy data trending in the "promising zone" and significantly improves the trials odds of success.

    Estimates are that vosaroxin can likely achieve peak annual sales of $700 million. Physicians are noting that vosaroxin likely will extend beyond the refractory AML setting such as first line settings when patients are at high risk of relapse or have cardiovascular issues.

    Dan Swisher - Cheif Executive Officer for Sunesis Pharmaceuticals, Inc. said: SNS has the cash through 2014, which is beyond several key milestones. Why is this important? (extremely low chance of dilution without significant share appreciation)

    RBC Capital believes that Phase III data for vosaroxin could surpass expectations. The firm thinks the company has a good chance of signing a partnership deal and they maintain an Outperform rating on their stock.

    This review establishes an opinion of: MARKET OUTPERFORM price target $20

    Investors will probably agree with this review using their due diligence/fact checking.

    Respectfully,
    Redstenox

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Vosaroxin for AML treatment has 2 phases, called induction and consolidation. Induction is the phase where the aim is to bring or induce your leukemia into remission (where leukemia is not detectable). Consolidation treatment can be given after your study doctor tells you that your leukemia is in remission. The aim of consolidation is to destroy any remaining leukemia cells. You may complete up to 4 cycles of therapy that can include 2 cycles of induction therapy, called induction 1 and induction 2, and up to 2 cycles of consolidation therapy, called consolidation 1 and 2. A cycle is 2 to 8 weeks, with 5 days of treatment followed by at least 9 days and up to 51 days without treatment to allow your blood cells to recover. In some cases, induction cycles can be as long as 12 weeks. The time for a cycle can depend on how your leukemia responds to the treatment, how quickly your bone marrow grows back normal blood cells after treatment, and if your study doctor feels it is okay for you to begin another cycle.

      Both SNSS and CYCC are despite some confusion good investments. SNSS's Valor trial seems to be meeting or exceeding expectations as seen by the safety monitoring boards expansion request and insider holding levels. No one is jumping ship here for fear of missing out on final results being released and meeting its endpoints.

      Investing in both companies SNSS and CYCC would be a sound course of action since both products offer differing approaches with the same end goal of helping people with no other options. These are not competing drugs in development rather complimentary drugs.

      • 2 Replies to arcashark
      • The buys here are from hidden pools and reserve orders... that's real buying

      • Sunesis Pharmaceuticals independent Data and Safety Monitoring Board reviewed the trial data and recommended the trial be expanded, suggesting that initial readings on efficacy are positive. The decision also gives Sunesis a $25 million cash infusion for achieving the milestone from Royalty Pharma, which in return gets warrants to buy additional stock and royalty payments on sales of vosaroxin if it ultimately gets approved. With Sunesis receiving from the U.S. patent office a Notice of Allowance earlier this year related to compositions used in vosaroxin that would provide exclusivity till 2030, it's no wonder Wall Street is unanimously exuberant. Of the analysts CAPS tracks, all seven that have weighed in on Sunesis Pharmaceuticals believe it will continue outperforming the broad market averages.

    • Sunesis Pharmaceuticals independent Data and Safety Monitoring Board reviewed the trial data and recommended the trial be expanded, suggesting that initial readings on efficacy are positive. The decision also gives Sunesis a $25 million cash infusion for achieving the milestone from Royalty Pharma, which in return gets warrants to buy additional stock and royalty payments on sales of vosaroxin if it ultimately gets approved. With Sunesis receiving from the U.S. patent office a "Notice of Allowance" earlier this year related to compositions used in vosaroxin that would provide exclusivity till 2030, it's no wonder Wall Street is unanimously exuberant. Of the analysts CAPS tracks, all seven that have weighed in on Sunesis Pharmaceuticals believe it will continue outperforming the broad market averages.

      • 1 Reply to arcashark
      • Sunesis Pharmaceuticals independent Data and Safety Monitoring Board reviewed the trial data and recommended the trial be expanded, suggesting that initial readings on efficacy are positive. The decision also gives Sunesis a $25 million cash infusion for achieving the milestone from Royalty Pharma, which in return gets warrants to buy additional stock and royalty payments on sales of vosaroxin if it ultimately gets approved. With Sunesis receiving from the U.S. patent office a "Notice of Allowance" earlier this year related to compositions used in vosaroxin that would provide exclusivity till 2030, it's no wonder Wall Street is unanimously exuberant. Of the analysts CAPS tracks, all seven that have weighed in on Sunesis Pharmaceuticals believe it will continue outperforming the broad market averages.

        Vosaroxin for AML treatment has 2 phases, called induction and consolidation. Induction is the phase where the aim is to bring or induce your leukemia into remission (where leukemia is not detectable). Consolidation treatment can be given after your study doctor tells you that your leukemia is in remission. The aim of consolidation is to destroy any remaining leukemia cells. You may complete up to 4 cycles of therapy that can include 2 cycles of induction therapy, called induction 1 and induction 2, and up to 2 cycles of consolidation therapy, called consolidation 1 and 2. A cycle is 2 to 8 weeks, with 5 days of treatment followed by at least 9 days and up to 51 days without treatment to allow your blood cells to recover. In some cases, induction cycles can be as long as 12 weeks. The time for a cycle can depend on how your leukemia responds to the treatment, how quickly your bone marrow grows back normal blood cells after treatment, and if your study doctor feels it is okay for you to begin another cycle.

        Both SNSS and CYCC are despite some confusion good investments. SNSS's Valor trial seems to be meeting or exceeding expectations as seen by the safety monitoring boards expansion request and insider holding levels. No one is jumping ship here for fear of missing out on final results being released and meeting its endpoints.

        Investing in both companies SNSS and CYCC would be a sound course of action since both products offer differing approaches with the same end goal of helping people with no other options. These are not competing drugs in development rather complimentary drugs.

    • Sunesis Pharmaceuticals independent Data and Safety Monitoring Board reviewed the trial data and recommended the trial be expanded, suggesting that initial readings on efficacy are positive. The decision also gives Sunesis a $25 million cash infusion for achieving the milestone from Royalty Pharma, which in return gets warrants to buy additional stock and royalty payments on sales of vosaroxin if it ultimately gets approved. With Sunesis receiving from the U.S. patent office a "Notice of Allowance" earlier this year related to compositions used in vosaroxin that would provide exclusivity till 2030, it's no wonder Wall Street is unanimously exuberant. Of the analysts CAPS tracks, all seven that have weighed in on Sunesis Pharmaceuticals believe it will continue outperforming the broad market averages.

      Vosaroxin for AML treatment has 2 phases, called induction and consolidation. Induction is the phase where the aim is to bring or induce your leukemia into remission (where leukemia is not detectable). Consolidation treatment can be given after your study doctor tells you that your leukemia is in remission. The aim of consolidation is to destroy any remaining leukemia cells. You may complete up to 4 cycles of therapy that can include 2 cycles of induction therapy, called induction 1 and induction 2, and up to 2 cycles of consolidation therapy, called consolidation 1 and 2. A cycle is 2 to 8 weeks, with 5 days of treatment followed by at least 9 days and up to 51 days without treatment to allow your blood cells to recover. In some cases, induction cycles can be as long as 12 weeks. The time for a cycle can depend on how your leukemia responds to the treatment, how quickly your bone marrow grows back normal blood cells after treatment, and if your study doctor feels it is okay for you to begin another cycle.

      Both SNSS and CYCC are despite some confusion good investments. SNSS's Valor trial seems to be meeting or exceeding expectations as seen by the safety monitoring boards expansion request and insider holding levels. No one is jumping ship here for fear of missing out on final results being released and meeting its endpoints.

      Investing in both companies SNSS and CYCC would be a sound course of action since both products offer differing approaches with the same end goal of helping people with no other options. These are not competing drugs in development rather complimentary drugs.

    • Sunesis Pharmaceuticals independent Data and Safety Monitoring Board reviewed the trial data and recommended the trial be expanded, suggesting that initial readings on efficacy are positive. The decision also gives Sunesis a $25 million cash infusion for achieving the milestone from Royalty Pharma, which in return gets warrants to buy additional stock and royalty payments on sales of vosaroxin if it ultimately gets approved. With Sunesis receiving from the U.S. patent office a "Notice of Allowance" earlier this year related to compositions used in vosaroxin that would provide exclusivity till 2030, it's no wonder Wall Street is unanimously exuberant. Of the analysts CAPS tracks, all seven that have weighed in on Sunesis Pharmaceuticals believe it will continue outperforming the broad market averages.

      Vosaroxin for AML treatment has 2 phases, called induction and consolidation. Induction is the phase where the aim is to bring or induce your leukemia into remission (where leukemia is not detectable). Consolidation treatment can be given after your study doctor tells you that your leukemia is in remission. The aim of consolidation is to destroy any remaining leukemia cells. You may complete up to 4 cycles of therapy that can include 2 cycles of induction therapy, called induction 1 and induction 2, and up to 2 cycles of consolidation therapy, called consolidation 1 and 2. A cycle is 2 to 8 weeks, with 5 days of treatment followed by at least 9 days and up to 51 days without treatment to allow your blood cells to recover. In some cases, induction cycles can be as long as 12 weeks. The time for a cycle can depend on how your leukemia responds to the treatment, how quickly your bone marrow grows back normal blood cells after treatment, and if your study doctor feels it is okay for you to begin another cycle.

      Both SNSS and CYCC are despite some confusion good investments. SNSS's Valor trial seems to be meeting or exceeding expectations as seen by the safety monitoring boards expansion request and insider holding levels. No one is jumping ship here for fear of missing out on final results being released and meeting its endpoints.

      Investing in both companies SNSS and CYCC would be a sound course of action since both products offer differing approaches with the same end goal of helping people with no other options. These are not competing drugs in development rather complimentary drugs.

    • Sunesis Pharmaceuticals independent Data and Safety Monitoring Board reviewed the trial data and recommended the trial be expanded, suggesting that initial readings on efficacy are positive. The decision also gives Sunesis a $25 million cash infusion for achieving the milestone from Royalty Pharma, which in return gets warrants to buy additional stock and royalty payments on sales of vosaroxin if it ultimately gets approved. With Sunesis receiving from the U.S. patent office a "Notice of Allowance" earlier this year related to compositions used in vosaroxin that would provide exclusivity till 2030, it's no wonder Wall Street is unanimously exuberant. Of the analysts CAPS tracks, all seven that have weighed in on Sunesis Pharmaceuticals believe it will continue outperforming the broad market averages.

      Vosaroxin for AML treatment has 2 phases, called induction and consolidation. Induction is the phase where the aim is to bring or induce your leukemia into remission (where leukemia is not detectable). Consolidation treatment can be given after your study doctor tells you that your leukemia is in remission. The aim of consolidation is to destroy any remaining leukemia cells. You may complete up to 4 cycles of therapy that can include 2 cycles of induction therapy, called induction 1 and induction 2, and up to 2 cycles of consolidation therapy, called consolidation 1 and 2. A cycle is 2 to 8 weeks, with 5 days of treatment followed by at least 9 days and up to 51 days without treatment to allow your blood cells to recover. In some cases, induction cycles can be as long as 12 weeks. The time for a cycle can depend on how your leukemia responds to the treatment, how quickly your bone marrow grows back normal blood cells after treatment, and if your study doctor feels it is okay for you to begin another cycle.

      Both SNSS and CYCC are despite some confusion good investments. SNSS's Valor trial seems to be meeting or exceeding expectations as seen by the safety monitoring boards expansion request and insider holding levels. No one is jumping ship here for fear of missing out on final results being released and meeting its endpoints.

      Investing in both companies SNSS and CYCC would be a sound course of action since both products offer differing approaches with the same end goal of helping people with no other options. These are not competing drugs in development rather complimentary drugs.

      • 1 Reply to arcashark
      • Sunesis Pharmaceuticals independent Data and Safety Monitoring Board reviewed the trial data and recommended the trial be expanded, suggesting that initial readings on efficacy are positive. The decision also gives Sunesis a $25 million cash infusion for achieving the milestone from Royalty Pharma, which in return gets warrants to buy additional stock and royalty payments on sales of vosaroxin if it ultimately gets approved. With Sunesis receiving from the U.S. patent office a "Notice of Allowance" earlier this year related to compositions used in vosaroxin that would provide exclusivity till 2030, it's no wonder Wall Street is unanimously exuberant. Of the analysts CAPS tracks, all seven that have weighed in on Sunesis Pharmaceuticals believe it will continue outperforming the broad market averages.

        Vosaroxin for AML treatment has 2 phases, called induction and consolidation. Induction is the phase where the aim is to bring or induce your leukemia into remission (where leukemia is not detectable). Consolidation treatment can be given after your study doctor tells you that your leukemia is in remission. The aim of consolidation is to destroy any remaining leukemia cells. You may complete up to 4 cycles of therapy that can include 2 cycles of induction therapy, called induction 1 and induction 2, and up to 2 cycles of consolidation therapy, called consolidation 1 and 2. A cycle is 2 to 8 weeks, with 5 days of treatment followed by at least 9 days and up to 51 days without treatment to allow your blood cells to recover. In some cases, induction cycles can be as long as 12 weeks. The time for a cycle can depend on how your leukemia responds to the treatment, how quickly your bone marrow grows back normal blood cells after treatment, and if your study doctor feels it is okay for you to begin another cycle.

        Both SNSS and CYCC are despite some confusion good investments. SNSS's Valor trial seems to be meeting or exceeding expectations as seen by the safety monitoring boards expansion request and insider holding levels. No one is jumping ship here for fear of missing out on final results being released and meeting its endpoints.

        Investing in both companies SNSS and CYCC would be a sound course of action since both products offer differing approaches with the same end goal of helping people with no other options. These are not competing drugs in development rather complimentary drugs.

    • Sunesis Pharmaceuticals independent Data and Safety Monitoring Board reviewed the trial data and recommended the trial be expanded, suggesting that initial readings on efficacy are positive. The decision also gives Sunesis a $25 million cash infusion for achieving the milestone from Royalty Pharma, which in return gets warrants to buy additional stock and royalty payments on sales of vosaroxin if it ultimately gets approved. With Sunesis receiving from the U.S. patent office a "Notice of Allowance" earlier this year related to compositions used in vosaroxin that would provide exclusivity till 2030, it's no wonder Wall Street is unanimously exuberant. Of the analysts CAPS tracks, all seven that have weighed in on Sunesis Pharmaceuticals believe it will continue outperforming the broad market averages.

      Vosaroxin for AML treatment has 2 phases, called induction and consolidation. Induction is the phase where the aim is to bring or induce your leukemia into remission (where leukemia is not detectable). Consolidation treatment can be given after your study doctor tells you that your leukemia is in remission. The aim of consolidation is to destroy any remaining leukemia cells. You may complete up to 4 cycles of therapy that can include 2 cycles of induction therapy, called induction 1 and induction 2, and up to 2 cycles of consolidation therapy, called consolidation 1 and 2. A cycle is 2 to 8 weeks, with 5 days of treatment followed by at least 9 days and up to 51 days without treatment to allow your blood cells to recover. In some cases, induction cycles can be as long as 12 weeks. The time for a cycle can depend on how your leukemia responds to the treatment, how quickly your bone marrow grows back normal blood cells after treatment, and if your study doctor feels it is okay for you to begin another cycle.

      Both SNSS and CYCC are despite some confusion good investments. SNSS's Valor trial seems to be meeting or exceeding expectations as seen by the safety monitoring boards expansion request and insider holding levels. No one is jumping ship here for fear of missing out on final results being released and meeting its endpoints.

      Investing in both companies SNSS and CYCC would be a sound course of action since both products offer differing approaches with the same end goal of helping people with no other options. These are not competing drugs in development rather complimentary drugs.

    • Sunesis Pharmaceuticals independent Data and Safety Monitoring Board reviewed the trial data and recommended the trial be expanded, suggesting that initial readings on efficacy are positive. The decision also gives Sunesis a $25 million cash infusion for achieving the milestone from Royalty Pharma, which in return gets warrants to buy additional stock and royalty payments on sales of vosaroxin if it ultimately gets approved. With Sunesis receiving from the U.S. patent office a "Notice of Allowance" earlier this year related to compositions used in vosaroxin that would provide exclusivity till 2030, it's no wonder Wall Street is unanimously exuberant. Of the analysts CAPS tracks, all seven that have weighed in on Sunesis Pharmaceuticals believe it will continue outperforming the broad market averages.

      Vosaroxin for AML treatment has 2 phases, called induction and consolidation. Induction is the phase where the aim is to bring or induce your leukemia into remission (where leukemia is not detectable). Consolidation treatment can be given after your study doctor tells you that your leukemia is in remission. The aim of consolidation is to destroy any remaining leukemia cells. You may complete up to 4 cycles of therapy that can include 2 cycles of induction therapy, called induction 1 and induction 2, and up to 2 cycles of consolidation therapy, called consolidation 1 and 2. A cycle is 2 to 8 weeks, with 5 days of treatment followed by at least 9 days and up to 51 days without treatment to allow your blood cells to recover. In some cases, induction cycles can be as long as 12 weeks. The time for a cycle can depend on how your leukemia responds to the treatment, how quickly your bone marrow grows back normal blood cells after treatment, and if your study doctor feels it is okay for you to begin another cycle.

      Both SNSS and CYCC are despite some confusion good investments. SNSS's Valor trial seems to be meeting or exceeding expectations as seen by the safety monitoring boards expansion request and insider holding levels. No one is jumping ship here for fear of missing out on final results being released and meeting its endpoints.

      Investing in both companies SNSS and CYCC would be a sound course of action since both products offer differing approaches with the same end goal of helping people with no other options. These are not competing drugs in development rather complimentary drugs.

    • Sunesis Pharmaceuticals independent Data and Safety Monitoring Board reviewed the trial data and recommended the trial be expanded, suggesting that initial readings on efficacy are positive. The decision also gives Sunesis a $25 million cash infusion for achieving the milestone from Royalty Pharma, which in return gets warrants to buy additional stock and royalty payments on sales of vosaroxin if it ultimately gets approved. With Sunesis receiving from the U.S. patent office a "Notice of Allowance" earlier this year related to compositions used in vosaroxin that would provide exclusivity till 2030, it's no wonder Wall Street is unanimously exuberant. Of the analysts CAPS tracks, all seven that have weighed in on Sunesis Pharmaceuticals believe it will continue outperforming the broad market averages.

      Vosaroxin for AML treatment has 2 phases, called induction and consolidation. Induction is the phase where the aim is to bring or induce your leukemia into remission (where leukemia is not detectable). Consolidation treatment can be given after your study doctor tells you that your leukemia is in remission. The aim of consolidation is to destroy any remaining leukemia cells. You may complete up to 4 cycles of therapy that can include 2 cycles of induction therapy, called induction 1 and induction 2, and up to 2 cycles of consolidation therapy, called consolidation 1 and 2. A cycle is 2 to 8 weeks, with 5 days of treatment followed by at least 9 days and up to 51 days without treatment to allow your blood cells to recover. In some cases, induction cycles can be as long as 12 weeks. The time for a cycle can depend on how your leukemia responds to the treatment, how quickly your bone marrow grows back normal blood cells after treatment, and if your study doctor feels it is okay for you to begin another cycle.

      Both SNSS and CYCC are despite some confusion good investments. SNSS's Valor trial seems to be meeting or exceeding expectations as seen by the safety monitoring boards expansion request and insider holding levels. No one is jumping ship here for fear of missing out on final results being released and meeting its endpoints.

      Investing in both companies SNSS and CYCC would be a sound course of action since both products offer differing approaches with the same end goal of helping people with no other options. These are not competing drugs in development rather complimentary drugs.

    • Sunesis Pharmaceuticals independent Data and Safety Monitoring Board reviewed the trial data and recommended the trial be expanded, suggesting that initial readings on efficacy are positive. The decision also gives Sunesis a $25 million cash infusion for achieving the milestone from Royalty Pharma, which in return gets warrants to buy additional stock and royalty payments on sales of vosaroxin if it ultimately gets approved. With Sunesis receiving from the U.S. patent office a "Notice of Allowance" earlier this year related to compositions used in vosaroxin that would provide exclusivity till 2030, it's no wonder Wall Street is unanimously exuberant. Of the analysts CAPS tracks, all seven that have weighed in on Sunesis Pharmaceuticals believe it will continue outperforming the broad market averages.

      • 1 Reply to arcashark
      • Sunesis Pharmaceuticals independent Data and Safety Monitoring Board reviewed the trial data and recommended the trial be expanded, suggesting that initial readings on efficacy are positive. The decision also gives Sunesis a $25 million cash infusion for achieving the milestone from Royalty Pharma, which in return gets warrants to buy additional stock and royalty payments on sales of vosaroxin if it ultimately gets approved. With Sunesis receiving from the U.S. patent office a "Notice of Allowance" earlier this year related to compositions used in vosaroxin that would provide exclusivity till 2030, it's no wonder Wall Street is unanimously exuberant. Of the analysts CAPS tracks, all seven that have weighed in on Sunesis Pharmaceuticals believe it will continue outperforming the broad market averages.

        Vosaroxin for AML treatment has 2 phases, called induction and consolidation. Induction is the phase where the aim is to bring or induce your leukemia into remission (where leukemia is not detectable). Consolidation treatment can be given after your study doctor tells you that your leukemia is in remission. The aim of consolidation is to destroy any remaining leukemia cells. You may complete up to 4 cycles of therapy that can include 2 cycles of induction therapy, called induction 1 and induction 2, and up to 2 cycles of consolidation therapy, called consolidation 1 and 2. A cycle is 2 to 8 weeks, with 5 days of treatment followed by at least 9 days and up to 51 days without treatment to allow your blood cells to recover. In some cases, induction cycles can be as long as 12 weeks. The time for a cycle can depend on how your leukemia responds to the treatment, how quickly your bone marrow grows back normal blood cells after treatment, and if your study doctor feels it is okay for you to begin another cycle.

        Both SNSS and CYCC are despite some confusion good investments. SNSS's Valor trial seems to be meeting or exceeding expectations as seen by the safety monitoring boards expansion request and insider holding levels. No one is jumping ship here for fear of missing out on final results being released and meeting its endpoints.

        Investing in both companies SNSS and CYCC would be a sound course of action since both products offer differing approaches with the same end goal of helping people with no other options. These are not competing drugs in development rather complimentary drugs.

    • Sunesis Pharmaceuticals independent Data and Safety Monitoring Board reviewed the trial data and recommended the trial be expanded, suggesting that initial readings on efficacy are positive. The decision also gives Sunesis a $25 million cash infusion for achieving the milestone from Royalty Pharma, which in return gets warrants to buy additional stock and royalty payments on sales of vosaroxin if it ultimately gets approved. With Sunesis receiving from the U.S. patent office a "Notice of Allowance" earlier this year related to compositions used in vosaroxin that would provide exclusivity till 2030, it's no wonder Wall Street is unanimously exuberant. Of the analysts CAPS tracks, all seven that have weighed in on Sunesis Pharmaceuticals believe it will continue outperforming the broad market averages.

      Vosaroxin for AML treatment has 2 phases, called induction and consolidation. Induction is the phase where the aim is to bring or induce your leukemia into remission (where leukemia is not detectable). Consolidation treatment can be given after your study doctor tells you that your leukemia is in remission. The aim of consolidation is to destroy any remaining leukemia cells. You may complete up to 4 cycles of therapy that can include 2 cycles of induction therapy, called induction 1 and induction 2, and up to 2 cycles of consolidation therapy, called consolidation 1 and 2. A cycle is 2 to 8 weeks, with 5 days of treatment followed by at least 9 days and up to 51 days without treatment to allow your blood cells to recover. In some cases, induction cycles can be as long as 12 weeks. The time for a cycle can depend on how your leukemia responds to the treatment, how quickly your bone marrow grows back normal blood cells after treatment, and if your study doctor feels it is okay for you to begin another cycle.

      Both SNSS and CYCC are despite some confusion good investments. SNSS's Valor trial seems to be meeting or exceeding expectations as seen by the safety monitoring boards expansion request and insider holding levels. No one is jumping ship here for fear of missing out on final results being released and meeting its endpoints.

      Investing in both companies SNSS and CYCC would be a sound course of action since both products offer differing approaches with the same end goal of helping people with no other options. These are not competing drugs in development rather complimentary drugs.

 
SNSS
6.92+0.18(+2.67%)Aug 22 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.